Acute ST-segment Elevation Myocardial Infarction Xagena

Acute ST-segment elevation myocardial infarction

News

Page 1 of 2

Clopidogrel plus Aspirin reduces myocardial infarction risk in patients with acute coronary syndrome: In order to better prevent blood clots, Clopidogrel ( Plavix ) can be prescribed to patients with acute ischaemia of the heart muscle, in addition to Acetylsalicylic acid ( ASA ). The Institute for Quality and Efficiency in Health Care ( IQWiG ) has now investigated whether the combination of Clopid...
Read Article

Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes: Recent changes in the recommended treatments used for patients hospitalized for acute coronary syndromes are associated with reductions in the rates of heart failure, stroke, myocardial infarction and death. Randomized trials have provided strong evidence for the effectiveness of pharmacological ...
Read Article

BNP test to predict cardiovascular risk in myocardial infarction patients not yet appropriately used: An analysis by researchers at the Duke Clinical Research Institute ( DCRI ) found that a new brain chemical test that predicts which patients with myocardial infarction symptoms are at higher risk of dying is paradoxically not being used in younger, healthier patients who could benefit the most from...
Read Article

Stem cell mobilization therapy appears to be ineffective in repairing damage caused by myocardial infarction: Therapy that involved bone marrow stem cells did not improve cardiac function in patients following a myocardial infarction. There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus openin...
Read Article

FDA has approved new use for Plavix: STEMI myocardial infarction: The FDA ( Food and Drug Administration ) has approved the use of Plavix ( Clopidogrel ) for treatment of acute ST-segment elevation myocardial infarction ( STEMI ), in patients who are not going to have angioplasty. FDA approved Plavix in November 1997 to decrease platelet function in people who...
Read Article

Tenecteplase-facilitated PCI in patients with ST-segment elevation acute myocardial infarction is not recommended: Primary percutaneous coronary intervention ( PCI ) is more effective than fibrinolytic therapy for ST-segment elevation acute myocardial infarction ( STEMI ), but time to intervention can be considerable. Researchers investigated whether the administration of full-dose Tenecteplase ( Metalyse/ TN...
Read Article

ASTAMI trial: no effect on left ventricular function by intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction: The role of intracoronary infusion of autologous bone marrow cells in the management of acute myocardial infarction was examined in the ASTAMI trial. The ASTAMI investigators limited enrollment to acute ST-segment elevation myocardial infarction patients with anterior wall involvement for 2 reaso...
Read Article

REPAIR-AMI trial: intracoronary infusion of bone marrow�derived progenitor cells in acute myocardial infarction: Despite advances in therapy for acute myocardial infarction, mortality and morbidity related to post�myocardial infarction left ventricular dysfunction remain high. To date, the clinical tools for preventing post- myocardial infarction heart failure have been limited to rapid reperfusion and posti...
Read Article

Excessive doses of antithrombotic therapy in patients with acute coronary syndromes: A prospective observational analysis, coordinated by the DCRI ( Duke Clinical Research Institute ), in 387 US hospitals of 30,136 patients from the CRUSADE database has found that patients with NSTE ACS (non�ST-segment elevation acute coronary syndromes ) treated in the community often receive exce...
Read Article

Acute coronary syndromes, Enoxaparin and unfractionated Heparin show similar outcomes at one year: A study, published in the JAMA, showed that high-risk patients with acute coronary syndromes ( ACS ) treated with an early revascularization strategy and Enoxaparin ( Clexane/Lovenox ) or unfractionated Heparin at the time of hospitalization for ACS had similar outcomes at one year, including remai...
Read Article

Pages:1, 2 Next

Farmaci

Home